Primer on Tumor Immunology and Cancer Immunotherapy™

Thursday, Nov. 8, 2018
8 a.m. – 5 p.m.

Program Purpose

Our understanding of cancer immunobiology has increased dramatically in recent years, leading to the successful development of novel immune-based treatment options to improve cancer patient outcomes. The SITC Primer on Tumor Immunology and Cancer Immunotherapy™ was designed to provide a foundation for understanding core immunology principles as they relate to basic and clinical research in immunotherapy of cancer.

Click here to view the full SITC 2018 schedule online or click here to download a PDF of the full SITC 2018 schedule.

Program Organizers

  • Timothy NJ Bullock, PhD – University of Virginia
  • Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine

Intended Audience

The intended audience for this annual, one-day educational program included students, postdoctoral fellows and technicians from academia and industry, as well as physicians and scientists at more senior levels who wish to solidify their understanding of tumor immunology and immunotherapy.

Educational Objectives

Upon completion of this meeting, participants are able to:

  • Describe the key principles of tumor immunology and immunotherapy
  • Summarize the basic principles of passive immunotherapy, in which antibodies or T lymphocytes generated outside of the patient are administered with therapeutic intent
  • Discuss the techniques involved in active immunotherapy, including tumor antigen vaccination as well as immune checkpoint blockade
  • Outline immune monitoring techniques, both in peripheral blood and sera, as well as in patient samples collected in pre-surgical trials
  • Enhance scientific exchange with colleagues and collaborators on research and application of cancer immunotherapies to improve outcomes of patients with cancer

Click here for information on continuing medical education credits available through the Primer on Tumor Immunology and Cancer Immunotherapy™.

The SITC Primer on Tumor Immunology and Cancer Immunotherapy™ was supported in part by a grant from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Incyte Corporation and Merck & Co., Inc.

Schedule At-a-Glance